Analysts’ Top Healthcare Picks: Simulations Plus (SLP), Stryker (SYK)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Simulations Plus (SLP) and Stryker (SYK) with bullish sentiments.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Simulations Plus (SLP)
In a report released today, Max Smock from William Blair reiterated a Buy rating on Simulations Plus. The company’s shares closed last Thursday at $12.99.
According to TipRanks.com, Smock ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Simulations Plus with a $16.00 average price target, representing a 25.0% upside. In a report issued on April 2, Craig-Hallum also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Stryker (SYK)
In a report released today, Matthew O’Brien from Piper Sandler reiterated a Buy rating on Stryker, with a price target of $420.00. The company’s shares closed last Thursday at $339.14.
According to TipRanks.com, O’Brien is ranked 0 out of 5 stars with an average return of
Stryker has an analyst consensus of Strong Buy, with a price target consensus of $426.68, representing a 26.2% upside. In a report issued on April 6, Evercore ISI also maintained a Buy rating on the stock with a $365.00 price target.
Read More on SLP:
Disclaimer & DisclosureReport an Issue
- Simulations Plus: Solid Q2 and Long-Term Potential Tempered by EPS Headwinds and Biopharma Spending Uncertainty Supporting Hold Rating
- Closing Bell Movers: Markets on edge ahead of US-Iran talks
- Simulations Plus Reports Q2 2026 Results, Trims EPS Outlook
- Simulations Plus reports Q2 adjusted EPS 35c, consensus 31c
- Simulations Plus cuts FY26 adjusted EPS view to 75c-85c from $1.03-$1.10
